Takeda Pharma (TKPYY) 22.8800 $TKPYY
Seattle Genetics Up on Narrower-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 3:20PM CDT
Seattle Genetics reported second-quarter loss per share of 14 cents, narrower than the Zacks Consensus Estimate of a loss of 22 cents.
AMAG Pharmaceuticals Q2 Loss Narrows as Feraheme Sales Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 12:50PM CDT
AMAG's (AMAG) second quarter loss narrowed on the back of increased Feraheme sales.
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2014
M2 - Wed Jul 30, 3:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/djdwhf/cognitive) has announced the addition of the "Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Eli Lilly and Company - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - Avineuro Pharmaceuticals, Inc. - Novartis AG - FORUM Pharmaceuticals Inc. - H. Lundbeck A/S - Pfizer Inc. - Suven Life Sciences Ltd. - Mithridion, Inc. - CoMentis, Inc. - Upsher-Smith Laboratories, Inc. - Siena Biotech S.p.A. - Dart NeuroScience LLC - Intra-Cellular Therapies, Inc. - Amarantus Bioscience Holdings, Inc. - Mnemosyne Pharmaceuticals, Inc. - SK Biopharmaceuticals Co., Ltd. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/djdwhf/cognitive
Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
Pipeline Analysis and Sales Projections of the Top 25 Pharmaceutical Companies 2013-2023
M2 - Wed Jul 23, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7pjm9m/top_25) has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. For each company, the report provides: - Revenues - R&D Spending 2007-2013 - Geographic Breakout of Revenues - Performance of Specific Products - Performance by Drug Category - Late-Stage Pipeline - Projections of Revenues to 2023 In addition to specific company data and factors, there are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. The companies included in the study are: - Pfizer, inc. - Novartis AG - Roche ltd. - Merck & Co., inc. - Sanofi - Glaxosmithkline PLC - Johnson & johnson - Astra Zeneca plc - Eli Lilly and Company - Abbvie, inc. - Teva Pharmaceutical Industries, Ltd. - Amgen, inc. - Bristol-myers Squibb Company - Takeda Pharmaceutical co., LTD - Bayer AG - Novo nordisk - Boehringer Ingelheim gmbh - Daiichi Sankyo - Astellas - Gilead Sciences - Otsuka Pharmaceutical - Merck KGAA - Actavis - Mylan - Baxter international For more information visit http://www.researchandmarkets.com/research/7pjm9m/top_25
Global Insomnia Clinical Trials Review, H2, 2014 Featuring 10 Companies & 10 Institutes
M2 - Thu Jul 17, 8:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xplssq/insomnia_global) has announced the addition of the "Insomnia Global Clinical Trials Review, H2, 2014" report to their offering. Insomnia Global Clinical Trials Review, H2, 2014" provides data on the Insomnia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Insomnia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Insomnia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Takeda Pharmaceutical Company Limited - Merck & Co., Inc. - Dainippon Sumitomo Pharma Co., Ltd. - Sanofi - Neurocrine Biosciences, Inc. - Pfizer Inc. - GlaxoSmithKline plc - Neurim Pharmaceuticals Ltd - Eisai Co., Ltd. - Actelion Ltd Clinical Trial Overview of Top Institutes / Government - University of Rochester - Duke University - U.S. Department of Veterans Affairs - Karolinska Institute - University of Pittsburgh - Brigham and Women's Hospital - Stanford University - The University of Hong Kong - Massachusetts General Hospital - National Institute of Mental Health For more information visit http://www.researchandmarkets.com/research/xp...nia_global
Lawsuit Settlement News Reports Bad Pharmaceutical Drug Cases Are Ongoing While Funding For Cash Advances and Free Attorney Legal Consultations Are Available
PR Newswire - Thu Jul 17, 4:00AM CDT
MT Services LLC, a Lawsuit Settlement News Reporting Company, which operates lawsuitsettlementnews.com announced today a primary focus on assisting plaintiffs of bad pharmaceutical drugs such as AndgroGel: Testosterone Creams, Accutane, Acetaminophen, Actos, Avandia, Byetta-Januvia-Victoza, Birth Control Products: Yaz, Yasmin, Ocella, Mirena, NuvaRing, Chantix, Crestor, Depakote, Fosamax, Granuflo, Lexapro, Lipitor, Paxil, Prempro, Pradaxa, Reglan, Risperdal, Steroid/Epidural Shots Causing Meningitis, Topamax, Viagra, Zoloft or others not listed on finding legal assistance with obtaining a pharmaceutical lawyer or law firm.
H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/748t6b/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Johnson & Johnson - Autoimmune Technologies, LLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Generex Biotechnology Corporation - Takeda Pharmaceutical Company Limited - Nanotherapeutics, Inc. - Novartis AG - CEL-SCI Corporation - OPKO Health, Inc. - Hemispherx Biopharma, Inc. - Medicago Inc. - BioDiem Ltd - NanoViricides, Inc. - Medigen Biotechnology Corporation - SIGA Technologies, Inc. - XOMA Corporation - Green Cross Corporation - Antigen Express, Inc. - Adimmune Corporation - TechnoVax, Inc. - Cocrystal Pharma, Inc. - PaxVax - Vivaldi Biosciences Inc. - Aprogen, Inc. - Akshaya Bio Inc. - Gemmus Pharma Inc. For more information visit http://www.researchandmarkets.com/research/74..._infection
Global Alzheimer's Drugs Market 2014-2018 with Eisai Co. Forest Laboratories, Janssen Pharmaceuticals & Novartis Dominating
M2 - Fri Jul 11, 9:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wldkgv/global) has announced the addition of the "Global Alzheimer's Drugs Market 2014-2018" report to their offering. The incidence rates for Alzheimer's disease are increasing, and the global Alzheimer's population is expected to double by 2030. Currently, it is estimated that 5 million Americans suffering from Alzheimer's disease are aged 65 years or above. This number might reach 13.8 million by 2050 as the baby boom generation ages. In the US, Alzheimer's disease is the fifth highest cause factor for deaths among people aged 65 years and above. It has been recognized as the only factor among the top 10 death-causing factors in America for which therapy is not available, preventing or slowing down the progression of disease. The number of deaths resulting from Alzheimer's disease increased by 68 percent during the period of 2000-2010 and this number is expected to increase further during the next decade. In the US, it is estimated that about 7,00,000 people aged 65 years or above will die from Alzheimer's disease in 2014. The incidence rate of Alzheimer's disease is increasing rapidly owing to a rise in the elderly population. In the US, the 2014 incidence rate of Alzheimer's disease for people aged 65 years or above is expected to reach 4,69,000 and this number is expected to double by 2050. According to the report, the Global Alzheimer's Drugs market is driven by several factors, of which the increase in the global aging population is one of the major drivers. The incidence of Alzheimer's disease is growing continuously, mainly because of an increase in the aging population, especially those aged 65 years or above. It is estimated about 596.8 million people will reach 65 years and above in 2014, and this number is expected to reach 681.2 million by 2018. Furthermore, the report states that one of the main challenges is the poor rate of Alzheimer's disease diagnosis. In developed economies, merely 20-50 percent of dementia cases are diagnosed while in developing economies such as India nearly 90 percent cases remain undiagnosed. The lack of diagnosis hampers the effective management of this disease. Key Vendors: - Eisai Co., Ltd. - Forest Laboratories Inc. - Janssen Pharmaceuticals Inc. - Novartis AG Other Prominent Vendors: - Adamas Pharmaceuticals Inc. - Archer Pharmaceuticals Inc. - Eli Lilly and Co. - F. Hoffmann-La Roche Ltd. - FORUM Pharmaceuticals Inc. - H. Lundbeck A/S - Merck & Co., Inc. - MorphoSys AG - Otsuka Pharmaceutical Development & Commercialization Inc./ Otsuka America Pharmaceutical, Inc. - Takeda Pharmaceutical Co., Ltd. - TauRx Pharmaceuticals Ltd. - Zinfandel Pharmaceuticals Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Disease Overview - Alzheimer's Disease - Market Landscape - Market Segmentation by MOA - Market Assessment of Top Drugs - Competitive Assessment of Top Drugs - Focus on Alzheimer's Research - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Future Vendors Expected To Tap the Market - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/wldkgv/global
Takeda and Zinfandel Pharmaceuticals to Present Data at Upcoming Alzheimer's Association International Conference® Highlighting Innovative Approaches to Alzheimer's Disease Research and Development
PR Newswire - Thu Jul 10, 8:00AM CDT
Takeda Pharmaceutical Company Limited ("Takeda"
and its partner, Zinfandel Pharmaceuticals, Inc. ("Zinfandel" , will present data during multiple poster and oral sessions at the upcoming Alzheimer's Association International Conference® 2014 (AAIC®), taking place in Copenhagen, Denmark from July 12-17, 2014.
Cognitive Impairment Associated With Schizophrenia (CIAS) Clinical Trials Review, H1, 2014
M2 - Tue Jul 08, 10:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/85qd7j/cognitive) has announced the addition of the "Cognitive Impairment Associated With Schizophrenia (CIAS) Global Clinical Trials Review, H1, 2014" report to their offering. Cognitive Impairment Associated With Schizophrenia (CIAS) Global Clinical Trials Review, H1, 2014" provides data on the Cognitive Impairment Associated With Schizophrenia (CIAS) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cognitive Impairment Associated With Schizophrenia (CIAS). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cognitive Impairment Associated With Schizophrenia (CIAS). Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - Pfizer Inc. - Novartis AG - Merck & Co., Inc. - AbbVie Inc. - Takeda Pharmaceutical Company Limited - Saniona AB - Johnson & Johnson - GlaxoSmithKline plc - VA Greater Los Angeles Healthcare Center - Hamamatsu University School of Medicine - Bronx Veterans Medical Research Foundation - Mashhad University of Medical Sciences - St. Marianna University School of Medicine - Yale University - Indiana University - Central South University - University of Southern Denmark - Northwestern University For more information visit http://www.researchandmarkets.com/research/85qd7j/cognitive
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials Review, H1, 2014
M2 - Tue Jul 08, 9:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n6tm85/chronic) has announced the addition of the "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Clinical Trials Review, H1, 2014" report to their offering. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Clinical Trials Review, H1, 2014" provides data on the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - CSL Limited - LFB S.A. - Biogen Idec Inc. - Takeda Pharmaceutical Company Limited - Octapharma AG - Novartis AG - Kedrion S.p.A. - Grifols, S.A. - Grifols Deutschland Gmbh - GeNeuro SA - National Center for Research Resources - Aarhus University - Erasmus MC - State University of New York at Buffalo - Stony Brook University - University of Cologne - Northwestern University - Centre Hospitalier Universitaire de Saint Etienne - Oregon Health and Science University - Rigshospitalet For more information visit http://www.researchandmarkets.com/research/n6tm85/chronic
Phosphodiesterase 4 (PDE-4) Inhibitors Competitor Analysis 2014
M2 - Mon Jun 30, 8:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qxlm9z/competitor) has announced the addition of the "Competitor Analysis: Phosphodiesterase 4 (PDE-4) Inhibitors" report to their offering. PDE-4 has become an attractive target for development of oral, inhaled and topical inhibitors for treatment of asthma, chronic obstructive pulmonary disease (COPD), psoriatic arthritis, psoriasis, atopic dermatitis and many more diseases. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. Phosphodiesterase 4 (PDE-4) inhibitors have attracted considerable interest as potential therapeutic agents for inflammatory diseases of the lung, the skin and the gastrointestinal tract, but recently also for diseases of the nervous system. PDE-4 inhibitors are known to reduce elevated cAMP concentrations in inflammatory cells, leading to inhibition of inflammatory response, relaxation of smooth muscle in the airway, and modulation of sensory nerves in the lung as well. Many first and second generation PDE-4 inhibitors have failed in early development due to low therapeutic ratios with nausea and emesis being the main adverse effects. Several PDE-4 inhibitors have advanced to late stage clinical development or even regulatory approval for treatment of COPD and psoriatic arthritis. Other inflammatory diseases for which PDE-4 inhibitors are being evaluated clinically, include psoriasis, atopic dermatitis, rosacea, allergic conjunctivitis, and multiple sclerosis. Age-associated memory impairment and Alzheimer's disease are also studied clinically as indications for PDE-4 inhibitors. The report includes a compilation of currently active projects in research and development of predominantly small molecules specifically or unspecifically inhibiting phosphodiesterase 4 (PDE-4). In addition, the report lists company-specific R&D pipelines of PDE-4 inhibitors. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage and additional comments with a hyperlink leading to the source of information Key Topics Covered: 1. Oral and Inhaled Non-Selective PDE-4 Inhibitors 2. Oral and Inhaled Seletive PDE-4 Inhibitors 3. Topical PDE-4 Inhibitors 4. Corporate PDE-4 Inhibitor R&D Pipelines Companies Mentioned - Alcon (a Novartis company) - Almirall - Anacor Pharmaceuticals - c-a-i-r Biosciences - Celgene - Chiesi Farmaceutici - Dainippon Sumitomo Pharma - Dart NeuroScience - Dermira - Eisai - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Kyorin Pharmaceutical - Maruho - MediciNova - Merck - Michael J. Fox Foundation - Orchid Chemicals & Pharmaceutical - Otsuka Pharmaceutical - Pharmaxis Sanofi - Takeda Pharmaceutical Co (Nycomed) - Tetra Discovery Partners - Verona Pharma For more information visit http://www.researchandmarkets.com/research/qxlm9z/competitor
Global Hypertension Drugs Market 2014-2018
M2 - Thu Jun 26, 10:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tw2n66/global) has announced the addition of the "Global Hypertension Drugs Market 2014-2018" report to their offering. The Global Hypertension Drugs market will grow at a CAGR of 1.2% to 2018 Hypertension, also referred as arterial hypertension or high BP, is a chronic medical condition in which the arterial blood pressure is elevated to an undesired level. Lifestyle habits such as diet, exercising, and smoking are the major causes of hypertension. Hypertension can damage organs and lead to several illnesses such as renal failure, aneurysm, heart failure, stroke, and heart attack. There are two types of hypertension: primary or essential and secondary. The Global Hypertension Drugs market can be categorized into eight segments: - Diuretics - ACE Inhibitors - ARBs - CCB - Beta Blockers - Alpha Blockers - Vasodilators - Renin Inhibitors To calculate the market size, the report considers the revenue generated from the sales of various hypertension drugs used in the treatment of pulmonary arterial hypertension and essential hypertension. The report, the Global Hypertension Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Hypertension Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Actelion Ltd. - AstraZeneca plc - Boehringer Ingelheim GmbH - Novartis AG - Pfizer Inc. - Sanofi SA Other Prominent Vendors - Bayer AG - Daiichi Sankyo Co. Ltd. - Forest Laboratories Inc. - Merck & Co. Inc. - Takeda Pharmaceutical Co. Ltd. - United Therapeutics Corp. - Valeant Pharmaceuticals International Inc. - XOMA LLC Key Market Drivers/Challenges/Trends - Increase in Aging Population. - Increasing Number of Patent Expirations. - Increasing Focus on Combination Therapies. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Late Stage Pipeline Snapshot - Market Segmentation by Mechanism of Action - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/tw2n66/global
Takeda Announces Termination of Orteronel (TAK-700) Development for Prostate Cancer in Japan, U.S.A. and Europe
Business Wire - Thu Jun 19, 1:00AM CDT
Takeda Pharmaceutical Company Limited (TSE:4502) announced today that it has voluntarily decided to end the development program for orteronel (TAK-700) for prostate cancer. The decision follows the results of two Phase 3 clinical trials in metastatic, castration resistant prostate cancer (mCRPC). The studies found while orteronel plus prednisone could extend the time patients lived before their cancer progressed, it did not extend overall survival in these patients. After careful consideration of the data from these trials, the company has determined that the drug has not demonstrated a clinical profile sufficient to move forward in mCRPC, given the availability of other therapies.
J&J's Velcade in Focus at the European Hematology Association - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 4:20PM CDT
Johnson & Johnson (JNJ) presented encouraging data from a phase III study on its oncology drug, Velcade, at the annual meeting of the European Hematology Association.
ENTYVIO(TM) (vedolizumab) Now Available in the United States for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis and Crohn's Disease
PR Newswire - Mon Jun 16, 9:00AM CDT
Takeda Pharmaceutical Company Limited ("Takeda" and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced the United States (U.S.) commercial availability of a new biologic therapy, ENTYVIO(TM) (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD).
New CONNECT Study Presents data on Measures of Cognitive Performance in Adult Patients Treated with Brintellix® (vortioxetine) for Major Depressive Disorder
PR Newswire - Mon Jun 16, 5:30AM CDT
Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced results from CONNECT, a new study that evaluated the effect of Brintellix 10-20 mg/d on aspects of cognitive function, using an objective neuropsychological test (the Digit Symbol Substitution Test or DSST) associated with executive function, processing speed and attention, in adults with major depressive disorder (MDD). The data will be presented as a late-breaker poster at the 29th International College of Neuropsychopharmacology (CINP) World Congress in Vancouver, Canada.
Affymax terminates Omontys' product collaboration and license agreement with Takeda
M2 - Mon Jun 16, 3:34AM CDT
Biopharmaceutical company Affymax (Other OTC:AFFY) revealed on Friday the termination of its Omontys (peginesatide) product collaboration and license agreement with Takeda Pharmaceutical Company of Osaka, Japan effective 10 September 2014.
Orexigen Slumps as Obesity Drug Approval Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 5:28PM CDT
Orexigen announced that the FDA has delayed the action date for its obesity candidate, NB32, by three months.
Seattle Genetics Up on Narrower-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 3:20PM CDT
Seattle Genetics reported second-quarter loss per share of 14 cents, narrower than the Zacks Consensus Estimate of a loss of 22 cents.
AMAG Pharmaceuticals Q2 Loss Narrows as Feraheme Sales Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 12:50PM CDT
AMAG's (AMAG) second quarter loss narrowed on the back of increased Feraheme sales.
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2014
M2 - Wed Jul 30, 3:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/djdwhf/cognitive) has announced the addition of the "Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Eli Lilly and Company - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - Avineuro Pharmaceuticals, Inc. - Novartis AG - FORUM Pharmaceuticals Inc. - H. Lundbeck A/S - Pfizer Inc. - Suven Life Sciences Ltd. - Mithridion, Inc. - CoMentis, Inc. - Upsher-Smith Laboratories, Inc. - Siena Biotech S.p.A. - Dart NeuroScience LLC - Intra-Cellular Therapies, Inc. - Amarantus Bioscience Holdings, Inc. - Mnemosyne Pharmaceuticals, Inc. - SK Biopharmaceuticals Co., Ltd. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/djdwhf/cognitive
Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
Pipeline Analysis and Sales Projections of the Top 25 Pharmaceutical Companies 2013-2023
M2 - Wed Jul 23, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7pjm9m/top_25) has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. For each company, the report provides: - Revenues - R&D Spending 2007-2013 - Geographic Breakout of Revenues - Performance of Specific Products - Performance by Drug Category - Late-Stage Pipeline - Projections of Revenues to 2023 In addition to specific company data and factors, there are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. The companies included in the study are: - Pfizer, inc. - Novartis AG - Roche ltd. - Merck & Co., inc. - Sanofi - Glaxosmithkline PLC - Johnson & johnson - Astra Zeneca plc - Eli Lilly and Company - Abbvie, inc. - Teva Pharmaceutical Industries, Ltd. - Amgen, inc. - Bristol-myers Squibb Company - Takeda Pharmaceutical co., LTD - Bayer AG - Novo nordisk - Boehringer Ingelheim gmbh - Daiichi Sankyo - Astellas - Gilead Sciences - Otsuka Pharmaceutical - Merck KGAA - Actavis - Mylan - Baxter international For more information visit http://www.researchandmarkets.com/research/7pjm9m/top_25
Global Insomnia Clinical Trials Review, H2, 2014 Featuring 10 Companies & 10 Institutes
M2 - Thu Jul 17, 8:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xplssq/insomnia_global) has announced the addition of the "Insomnia Global Clinical Trials Review, H2, 2014" report to their offering. Insomnia Global Clinical Trials Review, H2, 2014" provides data on the Insomnia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Insomnia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Insomnia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Takeda Pharmaceutical Company Limited - Merck & Co., Inc. - Dainippon Sumitomo Pharma Co., Ltd. - Sanofi - Neurocrine Biosciences, Inc. - Pfizer Inc. - GlaxoSmithKline plc - Neurim Pharmaceuticals Ltd - Eisai Co., Ltd. - Actelion Ltd Clinical Trial Overview of Top Institutes / Government - University of Rochester - Duke University - U.S. Department of Veterans Affairs - Karolinska Institute - University of Pittsburgh - Brigham and Women's Hospital - Stanford University - The University of Hong Kong - Massachusetts General Hospital - National Institute of Mental Health For more information visit http://www.researchandmarkets.com/research/xp...nia_global
Lawsuit Settlement News Reports Bad Pharmaceutical Drug Cases Are Ongoing While Funding For Cash Advances and Free Attorney Legal Consultations Are Available
PR Newswire - Thu Jul 17, 4:00AM CDT
MT Services LLC, a Lawsuit Settlement News Reporting Company, which operates lawsuitsettlementnews.com announced today a primary focus on assisting plaintiffs of bad pharmaceutical drugs such as AndgroGel: Testosterone Creams, Accutane, Acetaminophen, Actos, Avandia, Byetta-Januvia-Victoza, Birth Control Products: Yaz, Yasmin, Ocella, Mirena, NuvaRing, Chantix, Crestor, Depakote, Fosamax, Granuflo, Lexapro, Lipitor, Paxil, Prempro, Pradaxa, Reglan, Risperdal, Steroid/Epidural Shots Causing Meningitis, Topamax, Viagra, Zoloft or others not listed on finding legal assistance with obtaining a pharmaceutical lawyer or law firm.
H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/748t6b/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Johnson & Johnson - Autoimmune Technologies, LLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Generex Biotechnology Corporation - Takeda Pharmaceutical Company Limited - Nanotherapeutics, Inc. - Novartis AG - CEL-SCI Corporation - OPKO Health, Inc. - Hemispherx Biopharma, Inc. - Medicago Inc. - BioDiem Ltd - NanoViricides, Inc. - Medigen Biotechnology Corporation - SIGA Technologies, Inc. - XOMA Corporation - Green Cross Corporation - Antigen Express, Inc. - Adimmune Corporation - TechnoVax, Inc. - Cocrystal Pharma, Inc. - PaxVax - Vivaldi Biosciences Inc. - Aprogen, Inc. - Akshaya Bio Inc. - Gemmus Pharma Inc. For more information visit http://www.researchandmarkets.com/research/74..._infection
Global Alzheimer's Drugs Market 2014-2018 with Eisai Co. Forest Laboratories, Janssen Pharmaceuticals & Novartis Dominating
M2 - Fri Jul 11, 9:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wldkgv/global) has announced the addition of the "Global Alzheimer's Drugs Market 2014-2018" report to their offering. The incidence rates for Alzheimer's disease are increasing, and the global Alzheimer's population is expected to double by 2030. Currently, it is estimated that 5 million Americans suffering from Alzheimer's disease are aged 65 years or above. This number might reach 13.8 million by 2050 as the baby boom generation ages. In the US, Alzheimer's disease is the fifth highest cause factor for deaths among people aged 65 years and above. It has been recognized as the only factor among the top 10 death-causing factors in America for which therapy is not available, preventing or slowing down the progression of disease. The number of deaths resulting from Alzheimer's disease increased by 68 percent during the period of 2000-2010 and this number is expected to increase further during the next decade. In the US, it is estimated that about 7,00,000 people aged 65 years or above will die from Alzheimer's disease in 2014. The incidence rate of Alzheimer's disease is increasing rapidly owing to a rise in the elderly population. In the US, the 2014 incidence rate of Alzheimer's disease for people aged 65 years or above is expected to reach 4,69,000 and this number is expected to double by 2050. According to the report, the Global Alzheimer's Drugs market is driven by several factors, of which the increase in the global aging population is one of the major drivers. The incidence of Alzheimer's disease is growing continuously, mainly because of an increase in the aging population, especially those aged 65 years or above. It is estimated about 596.8 million people will reach 65 years and above in 2014, and this number is expected to reach 681.2 million by 2018. Furthermore, the report states that one of the main challenges is the poor rate of Alzheimer's disease diagnosis. In developed economies, merely 20-50 percent of dementia cases are diagnosed while in developing economies such as India nearly 90 percent cases remain undiagnosed. The lack of diagnosis hampers the effective management of this disease. Key Vendors: - Eisai Co., Ltd. - Forest Laboratories Inc. - Janssen Pharmaceuticals Inc. - Novartis AG Other Prominent Vendors: - Adamas Pharmaceuticals Inc. - Archer Pharmaceuticals Inc. - Eli Lilly and Co. - F. Hoffmann-La Roche Ltd. - FORUM Pharmaceuticals Inc. - H. Lundbeck A/S - Merck & Co., Inc. - MorphoSys AG - Otsuka Pharmaceutical Development & Commercialization Inc./ Otsuka America Pharmaceutical, Inc. - Takeda Pharmaceutical Co., Ltd. - TauRx Pharmaceuticals Ltd. - Zinfandel Pharmaceuticals Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Disease Overview - Alzheimer's Disease - Market Landscape - Market Segmentation by MOA - Market Assessment of Top Drugs - Competitive Assessment of Top Drugs - Focus on Alzheimer's Research - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Future Vendors Expected To Tap the Market - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/wldkgv/global
Takeda and Zinfandel Pharmaceuticals to Present Data at Upcoming Alzheimer's Association International Conference® Highlighting Innovative Approaches to Alzheimer's Disease Research and Development
PR Newswire - Thu Jul 10, 8:00AM CDT
Takeda Pharmaceutical Company Limited ("Takeda"
and its partner, Zinfandel Pharmaceuticals, Inc. ("Zinfandel" , will present data during multiple poster and oral sessions at the upcoming Alzheimer's Association International Conference® 2014 (AAIC®), taking place in Copenhagen, Denmark from July 12-17, 2014. Cognitive Impairment Associated With Schizophrenia (CIAS) Clinical Trials Review, H1, 2014
M2 - Tue Jul 08, 10:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/85qd7j/cognitive) has announced the addition of the "Cognitive Impairment Associated With Schizophrenia (CIAS) Global Clinical Trials Review, H1, 2014" report to their offering. Cognitive Impairment Associated With Schizophrenia (CIAS) Global Clinical Trials Review, H1, 2014" provides data on the Cognitive Impairment Associated With Schizophrenia (CIAS) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cognitive Impairment Associated With Schizophrenia (CIAS). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cognitive Impairment Associated With Schizophrenia (CIAS). Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - Pfizer Inc. - Novartis AG - Merck & Co., Inc. - AbbVie Inc. - Takeda Pharmaceutical Company Limited - Saniona AB - Johnson & Johnson - GlaxoSmithKline plc - VA Greater Los Angeles Healthcare Center - Hamamatsu University School of Medicine - Bronx Veterans Medical Research Foundation - Mashhad University of Medical Sciences - St. Marianna University School of Medicine - Yale University - Indiana University - Central South University - University of Southern Denmark - Northwestern University For more information visit http://www.researchandmarkets.com/research/85qd7j/cognitive
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials Review, H1, 2014
M2 - Tue Jul 08, 9:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n6tm85/chronic) has announced the addition of the "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Clinical Trials Review, H1, 2014" report to their offering. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Clinical Trials Review, H1, 2014" provides data on the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - CSL Limited - LFB S.A. - Biogen Idec Inc. - Takeda Pharmaceutical Company Limited - Octapharma AG - Novartis AG - Kedrion S.p.A. - Grifols, S.A. - Grifols Deutschland Gmbh - GeNeuro SA - National Center for Research Resources - Aarhus University - Erasmus MC - State University of New York at Buffalo - Stony Brook University - University of Cologne - Northwestern University - Centre Hospitalier Universitaire de Saint Etienne - Oregon Health and Science University - Rigshospitalet For more information visit http://www.researchandmarkets.com/research/n6tm85/chronic
Phosphodiesterase 4 (PDE-4) Inhibitors Competitor Analysis 2014
M2 - Mon Jun 30, 8:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qxlm9z/competitor) has announced the addition of the "Competitor Analysis: Phosphodiesterase 4 (PDE-4) Inhibitors" report to their offering. PDE-4 has become an attractive target for development of oral, inhaled and topical inhibitors for treatment of asthma, chronic obstructive pulmonary disease (COPD), psoriatic arthritis, psoriasis, atopic dermatitis and many more diseases. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. Phosphodiesterase 4 (PDE-4) inhibitors have attracted considerable interest as potential therapeutic agents for inflammatory diseases of the lung, the skin and the gastrointestinal tract, but recently also for diseases of the nervous system. PDE-4 inhibitors are known to reduce elevated cAMP concentrations in inflammatory cells, leading to inhibition of inflammatory response, relaxation of smooth muscle in the airway, and modulation of sensory nerves in the lung as well. Many first and second generation PDE-4 inhibitors have failed in early development due to low therapeutic ratios with nausea and emesis being the main adverse effects. Several PDE-4 inhibitors have advanced to late stage clinical development or even regulatory approval for treatment of COPD and psoriatic arthritis. Other inflammatory diseases for which PDE-4 inhibitors are being evaluated clinically, include psoriasis, atopic dermatitis, rosacea, allergic conjunctivitis, and multiple sclerosis. Age-associated memory impairment and Alzheimer's disease are also studied clinically as indications for PDE-4 inhibitors. The report includes a compilation of currently active projects in research and development of predominantly small molecules specifically or unspecifically inhibiting phosphodiesterase 4 (PDE-4). In addition, the report lists company-specific R&D pipelines of PDE-4 inhibitors. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage and additional comments with a hyperlink leading to the source of information Key Topics Covered: 1. Oral and Inhaled Non-Selective PDE-4 Inhibitors 2. Oral and Inhaled Seletive PDE-4 Inhibitors 3. Topical PDE-4 Inhibitors 4. Corporate PDE-4 Inhibitor R&D Pipelines Companies Mentioned - Alcon (a Novartis company) - Almirall - Anacor Pharmaceuticals - c-a-i-r Biosciences - Celgene - Chiesi Farmaceutici - Dainippon Sumitomo Pharma - Dart NeuroScience - Dermira - Eisai - Forest Laboratories - Gilead Sciences - GlaxoSmithKline - Kyorin Pharmaceutical - Maruho - MediciNova - Merck - Michael J. Fox Foundation - Orchid Chemicals & Pharmaceutical - Otsuka Pharmaceutical - Pharmaxis Sanofi - Takeda Pharmaceutical Co (Nycomed) - Tetra Discovery Partners - Verona Pharma For more information visit http://www.researchandmarkets.com/research/qxlm9z/competitor
Global Hypertension Drugs Market 2014-2018
M2 - Thu Jun 26, 10:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tw2n66/global) has announced the addition of the "Global Hypertension Drugs Market 2014-2018" report to their offering. The Global Hypertension Drugs market will grow at a CAGR of 1.2% to 2018 Hypertension, also referred as arterial hypertension or high BP, is a chronic medical condition in which the arterial blood pressure is elevated to an undesired level. Lifestyle habits such as diet, exercising, and smoking are the major causes of hypertension. Hypertension can damage organs and lead to several illnesses such as renal failure, aneurysm, heart failure, stroke, and heart attack. There are two types of hypertension: primary or essential and secondary. The Global Hypertension Drugs market can be categorized into eight segments: - Diuretics - ACE Inhibitors - ARBs - CCB - Beta Blockers - Alpha Blockers - Vasodilators - Renin Inhibitors To calculate the market size, the report considers the revenue generated from the sales of various hypertension drugs used in the treatment of pulmonary arterial hypertension and essential hypertension. The report, the Global Hypertension Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Hypertension Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Actelion Ltd. - AstraZeneca plc - Boehringer Ingelheim GmbH - Novartis AG - Pfizer Inc. - Sanofi SA Other Prominent Vendors - Bayer AG - Daiichi Sankyo Co. Ltd. - Forest Laboratories Inc. - Merck & Co. Inc. - Takeda Pharmaceutical Co. Ltd. - United Therapeutics Corp. - Valeant Pharmaceuticals International Inc. - XOMA LLC Key Market Drivers/Challenges/Trends - Increase in Aging Population. - Increasing Number of Patent Expirations. - Increasing Focus on Combination Therapies. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Late Stage Pipeline Snapshot - Market Segmentation by Mechanism of Action - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/tw2n66/global
Takeda Announces Termination of Orteronel (TAK-700) Development for Prostate Cancer in Japan, U.S.A. and Europe
Business Wire - Thu Jun 19, 1:00AM CDT
Takeda Pharmaceutical Company Limited (TSE:4502) announced today that it has voluntarily decided to end the development program for orteronel (TAK-700) for prostate cancer. The decision follows the results of two Phase 3 clinical trials in metastatic, castration resistant prostate cancer (mCRPC). The studies found while orteronel plus prednisone could extend the time patients lived before their cancer progressed, it did not extend overall survival in these patients. After careful consideration of the data from these trials, the company has determined that the drug has not demonstrated a clinical profile sufficient to move forward in mCRPC, given the availability of other therapies.
J&J's Velcade in Focus at the European Hematology Association - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 4:20PM CDT
Johnson & Johnson (JNJ) presented encouraging data from a phase III study on its oncology drug, Velcade, at the annual meeting of the European Hematology Association.
ENTYVIO(TM) (vedolizumab) Now Available in the United States for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis and Crohn's Disease
PR Newswire - Mon Jun 16, 9:00AM CDT
Takeda Pharmaceutical Company Limited ("Takeda"
and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced the United States (U.S.) commercial availability of a new biologic therapy, ENTYVIO(TM) (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD). New CONNECT Study Presents data on Measures of Cognitive Performance in Adult Patients Treated with Brintellix® (vortioxetine) for Major Depressive Disorder
PR Newswire - Mon Jun 16, 5:30AM CDT
Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced results from CONNECT, a new study that evaluated the effect of Brintellix 10-20 mg/d on aspects of cognitive function, using an objective neuropsychological test (the Digit Symbol Substitution Test or DSST) associated with executive function, processing speed and attention, in adults with major depressive disorder (MDD). The data will be presented as a late-breaker poster at the 29th International College of Neuropsychopharmacology (CINP) World Congress in Vancouver, Canada.
Affymax terminates Omontys' product collaboration and license agreement with Takeda
M2 - Mon Jun 16, 3:34AM CDT
Biopharmaceutical company Affymax (Other OTC:AFFY) revealed on Friday the termination of its Omontys (peginesatide) product collaboration and license agreement with Takeda Pharmaceutical Company of Osaka, Japan effective 10 September 2014.
Orexigen Slumps as Obesity Drug Approval Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 5:28PM CDT
Orexigen announced that the FDA has delayed the action date for its obesity candidate, NB32, by three months.
